In a report issued on April 26, Joel Beatty from Robert W. Baird maintained a Buy rating on Ambrx Biopharma (AMAM – Research Report), with a price target of $16.00. The company's shares closed last Friday at $3.81, close to its 52-week low of $3.50. According to TipRanks.com, Beatty is a 1-star analyst with an average return of -0.6% and a 41.5% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical. Ambrx Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.
https://www.tipranks.com/news/blurbs/robert-w-baird-thinks-ambrx-biopharmas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral